ESMO 2021: Real-World Treatment Patterns in Metastatic Hormone-Sensitive Prostate Cancer Patients in the US
ESMO 2021 real-world treatment patterns among patients with metastatic hormone-sensitive prostate cancer (mHSPC).
ESMO 2021 real-world treatment patterns among patients with metastatic hormone-sensitive prostate cancer (mHSPC).
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and…
Zach Klaassen and Alexander Cole discuss the impact of climate change on cancer screening, highlighting a study that explores public awareness of climate change’s health…
Ruchika Talwar hosts Natasha Gupta to explore the overlooked perspective of female partners in prostate cancer care. Dr. Gupta delves into her study on the…
Renal Cell Carcinoma (RCC), Advanced Renal Cell Carcinoma, vascular endothelial growth factor receptor (VEGF-R), Axitinib, adverse events of Axitinib treatment, mTOR inhibitors, tyrosine kinase inhibitors…
Zach Klaassen facilitates a conversation on the continuum of care in metastatic hormone-sensitive prostate cancer (mHSPC) with Jason Hafron and Elisabeth Heath. The discussion underscores…
Zachary Klaassen interviews Henrik Grönberg about the ProBio trial, presented at ESMO 2023. The ProBio trial, designed in 2019, is a platform trial aimed at…
bladder cancer, Non-Muscle Invasive Bladder Cancer (NMBIC), OncoTherad, Immunotherapy Associated with Platelet-Rich Plasma, high-risk non-muscular invasive bladder cancer (HRNMIBC), Toll-like Receptor (TLR), Toll-like Receptor agonists,…
Benjamin Lowentritt discusses metastatic hormone-sensitive prostate cancer (mHSPC) patients’ responses to ADT combined with enzalutamide or apalutamide. Dr. Lowentritt explains the study’s methodology, emphasizing the…
holmium laser enucleation of the prostate (HoLEP), holmium laser enucleation, enlarged prostate, benign prostate enlargment, Benign prostatic hyperplasia (BPH), urethral strictures.
high-grade non-muscle-invasive bladder cancer (HGNMIBC), non-muscle-invasive bladder cancer (NMIBC), NCT02324582, BCG therapy, post-BCG treatment, phase I dose-escalation trial.